Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial - Concepedia

Concepedia

Publication | Open Access

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

DOI Full Paper Access

335

Citations

28

References

2021

Year

Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V. Kowdley, Michelle Lai, Eugene R. Schiff, Pankaj Patel,

Abstract

Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).

References

	Year	Citations
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk David C. Goff, Donald M. Lloyd‐Jones, Glen C. Bennett, Journal of the American College of Cardiology	2013	4.9K
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆ Christi A Matteoni, Zobair M. Younossi, T GRAMLICH, Gastroenterology ObesityMetabolic SyndromeMetabolic Associated SteatohepatitisHepatic DisordersHepatology	1999	3.4K
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley, New England Journal of Medicine	2010	3.2K
Nonalcoholic Fatty Liver Disease Giulio Marchesini, Mara Brizi, Giampaolo Bianchi, Diabetes	2001	2.6K
Association of nonalcoholic fatty liver disease with insulin resistance Giulio Marchesini, Mara Brizi, Antonio Maria Morselli‐Labate, The American Journal of Medicine Insulin ResistanceObesityMetabolic SyndromeMetabolic Associated SteatohepatitisHepatology	1999	1.6K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study Eduardo Vilar‐Gómez, Luis Calzadilla Bertot, Vincent Wai‐Sun Wong, Gastroenterology Disease ProgressionFatty Liver DiseaseObesityMetabolic SyndromeMetabolic Associated Steatotic Liver Disease	2018	765
CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance Suryaprakash Raichur, Siew Tein Wang, Puck Wee Chan, Cell Metabolism Insulin ResistanceMetabolic SyndromeObesityInflammationDiet-induced Steatohepatitis	2014	445
The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Hepatology	2017	400
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis Brian C. Ferslew, Guoxiang Xie, Curtis Johnston, Digestive Diseases and Sciences Metabolic Associated SteatohepatitisHepatologyNonalcoholic Fatty Liver DiseaseMedicineLiver Physiology	2015	325

Page 1